Knight Therapeutics And Sumitomo Pharma Enter Into Exclusive Licensing Agreements To Commercialize Sumitomo'S Canadian Portfolio

Published: 2025-06-05 07:17:30 ET GUD.TO

Published on 06/05/2025 at 07:17